Original Title: 알레르기 비염, 천식에서 설하면역요법과 피하주사면역요법의 임상적 유용성 비교

Authors' recommendations: Disease burdens of allergic rhinitis and asthma have recently been on the rise, and Korea is not an exception. This study aims (Ed note: purpose statements should be in present tense) to review the effectiveness and safety of immunotherapy for the treatment of allergic rhinitis and asthma, and review efficient therapeutic options with economic aspects also taken into account. 1. Systematic Review First, the systemic review was aimed to verify the effectiveness and safety of sublingual and/or subcutaneous immunotherapy in allergic rhinitis and asthma. A total of 167 articles were finally selected for this study through the inclusion/exclusion procedures; 115 pertained to studies comparing sublingual immunotherapy (SLIT) versus placebo, 45 were regarding subcutaneous immunotherapy (SCIT) versus placebo, and 9 were comparative literature of sublingual versus subcutaneous immunotherapy. In this study, we could not conclude that two immunotherapies are different in subjects to allergic rhinitis and asthma. 2. Retrospective study The retrospective study was designed to find the real cost of immunotherapy in patients with allergic rhinitis and/or asthma. Medical records of a total of 161 patients were collected. As a result, the total cost of SCIT for 3 years of allergic rhinitis was estimated to be KRW 6,492,401 in adults and KRW 5,090,494 in children. SLIT for allergic rhinitis was estimated to be KRW 7,926,433 in adults and KRW 7,302,680 in children. The total cost of asthma was higher than for allergic rhinitis. For SCIT, the estimated cost was KRW 7,701,629 in adults and KRW 6,105,060 in children. The SLIT cost for asthma was estimated to be KRW 8,915,343 in adults and KRW 8,077,023 in children.

Project Status: Completed

Year Published: 2012

URL for published report: https://www.neca.re.kr/lay1/program/S1T11C145/report/view.do?seq=121

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: South Korea

Organisation Name: National Evidence-based healthcare Collaborating Agency

Contact Address: National Evidence-based Healthcare Collaborating Agency (NECA), 3~5F Health and Welfare Social Administration B/D, 400 Neungdong-ro, Gwangjin-gu, Seoul, Korea.

Contact Name: int@neca.re.kr

Contact Email: int@neca.re.kr

Copyright: National Evidence-based Healthcare Collaborating Agency (NECA)